Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechNavio | PRODUCT CODE: 1581094

Cover Image

PUBLISHER: TechNavio | PRODUCT CODE: 1581094

Acute Myeloid Leukemia (AML) Treatment Market in APAC 2024-2028

PUBLISHED:
PAGES: 126 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2500
PDF (Enterprise License)
USD 4000

Add to Cart

The acute myeloid leukemia (AML) treatment market in apac is forecasted to grow by USD 305.8 mn during 2023-2028, accelerating at a CAGR of 13.9% during the forecast period. The report on the acute myeloid leukemia (AML) treatment market in apac provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high incidence of acute myeloid leukemia, advancement in pharmacology and molecular biology in apac, and rising adoption of generic drugs.

Technavio's acute myeloid leukemia (AML) treatment market in apac is segmented as below:

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 202411.6%
CAGR13.9%
Incremental Value$305.8 mn

By Type

    • Chemotherapy
    • Stem cell transplantation
    • Others

By Geographical Landscape

    • APAC

This study identifies the car t-cell therapy for aml as one of the prime reasons driving the acute myeloid leukemia (AML) treatment market in apac growth during the next few years. Also, approval of new treatment methods for acute myeloid leukemia and rising number of awareness programs will lead to sizable demand in the market.

The report on the acute myeloid leukemia (AML) treatment market in apac covers the following areas:

    • Acute Myeloid Leukemia (AML) Treatment Market in APAC sizing
    • Acute Myeloid Leukemia (AML) Treatment Market in APAC forecast
    • Acute Myeloid Leukemia (AML) Treatment Market in APAC industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading acute myeloid leukemia (AML) treatment market in apac vendors that include AbbVie Inc., Agios Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bristol Myers Squibb Co., CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., MEI Pharma Inc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the acute myeloid leukemia (AML) treatment market in apac analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72532

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Country Market Characteristics
    • Executive Summary - Chart on Market By Geographical Landscape
    • Executive Summary - Chart on Market Segmentation by Type
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Parent Market
    • Data Table on - Parent Market
  • 2.2 Market characteristics
    • Market characteristics analysis
  • 2.3 Value chain analysis
    • Value Chain Analysis

3 Market Sizing

  • 3.1 Market definition
    • Offerings of companies included in the market definition
  • 3.2 Market segment analysis
    • Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
    • Chart on APAC - Market size and forecast 2023-2028 ($ million)
    • Data Table on Regional - Market size and forecast 2023-2028 ($ million)
    • Chart on APAC: Year-over-year growth 2023-2028 (%)
    • Data Table on Regional - Market size and forecast 2023-2028 ($ million)

4 Historic Market Size

  • 4.1 Acute Myeloid Leukemia (AML) Treatment Market in APAC 2018 - 2022
    • Historic Market Size - Data Table on Acute Myeloid Leukemia (AML) Treatment Market in APAC 2018 - 2022 ($ million)
  • 4.2 Type segment analysis 2018 - 2022
    • Historic Market Size - Type Segment 2018 - 2022 ($ million)
  • 4.3 Geography segment analysis 2018 - 2022
    • Historic Market Size - Geography Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
    • Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
    • Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
    • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
    • Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
    • Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
    • Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
    • Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

  • 6.1 Market segments
    • Chart on Type - Market share 2023-2028 (%)
    • Data Table on Type - Market share 2023-2028 (%)
  • 6.2 Comparison by Type
    • Chart on Comparison by Type
    • Data Table on Comparison by Type
  • 6.3 Chemotherapy - Market size and forecast 2023-2028
    • Chart on Chemotherapy - Market size and forecast 2023-2028 ($ million)
    • Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ million)
    • Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
    • Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
  • 6.4 Stem cell transplantation - Market size and forecast 2023-2028
    • Chart on Stem cell transplantation - Market size and forecast 2023-2028 ($ million)
    • Data Table on Stem cell transplantation - Market size and forecast 2023-2028 ($ million)
    • Chart on Stem cell transplantation - Year-over-year growth 2023-2028 (%)
    • Data Table on Stem cell transplantation - Year-over-year growth 2023-2028 (%)
  • 6.5 Others - Market size and forecast 2023-2028
    • Chart on Others - Market size and forecast 2023-2028 ($ million)
    • Data Table on Others - Market size and forecast 2023-2028 ($ million)
    • Chart on Others - Year-over-year growth 2023-2028 (%)
    • Data Table on Others - Year-over-year growth 2023-2028 (%)
  • 6.6 Market opportunity by Type
    • Market opportunity by Type ($ million)
    • Data Table on Market opportunity by Type ($ million)

7 Customer Landscape

  • 7.1 Customer landscape overview
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

  • 8.1 Geographic segmentation
    • Chart on Market share By Geographical Landscape - 2023-2028 (%)
    • Data Table on Market share By Geographical Landscape - 2023-2028 (%)
  • 8.2 Geographic comparison
    • Chart on Geographic comparison
    • Data Table on Geographic comparison
  • 8.3 China - Market size and forecast 2023-2028
    • Chart on China - Market size and forecast 2023-2028 ($ million)
    • Data Table on China - Market size and forecast 2023-2028 ($ million)
    • Chart on China - Year-over-year growth 2023-2028 (%)
    • Data Table on China - Year-over-year growth 2023-2028 (%)
  • 8.4 Japan - Market size and forecast 2023-2028
    • Chart on Japan - Market size and forecast 2023-2028 ($ million)
    • Data Table on Japan - Market size and forecast 2023-2028 ($ million)
    • Chart on Japan - Year-over-year growth 2023-2028 (%)
    • Data Table on Japan - Year-over-year growth 2023-2028 (%)
  • 8.5 India - Market size and forecast 2023-2028
    • Chart on India - Market size and forecast 2023-2028 ($ million)
    • Data Table on India - Market size and forecast 2023-2028 ($ million)
    • Chart on India - Year-over-year growth 2023-2028 (%)
    • Data Table on India - Year-over-year growth 2023-2028 (%)
  • 8.6 Rest of APAC - Market size and forecast 2023-2028
    • Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million)
    • Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million)
    • Chart on Rest of APAC - Year-over-year growth 2023-2028 (%)
    • Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%)
  • 8.7 Market opportunity By Geographical Landscape
    • Market opportunity By Geographical Landscape ($ million)
    • Data Table on Market opportunity By Geographical Landscape ($ million)

9 Drivers, Challenges, and Opportunity/Restraints

  • 9.1 Market drivers
  • 9.2 Market challenges
  • 9.3 Impact of drivers and challenges
    • Impact of drivers and challenges in 2023 and 2028
  • 9.4 Market opportunities/restraints

10 Competitive Landscape

  • 10.1 Overview
  • 10.2 Competitive Landscape
    • Overview on criticality of inputs and factors of differentiation
  • 10.3 Landscape disruption
    • Overview on factors of disruption
  • 10.4 Industry risks
    • Impact of key risks on business

11 Competitive Analysis

  • 11.1 Companies profiled
    • Companies covered
  • 11.2 Market positioning of companies
    • Matrix on companies position and classification
  • 11.3 AbbVie Inc.
    • AbbVie Inc. - Overview
    • AbbVie Inc. - Product / Service
    • AbbVie Inc. - Key news
    • AbbVie Inc. - Key offerings
  • 11.4 Agios Inc.
    • Agios Inc. - Overview
    • Agios Inc. - Product / Service
    • Agios Inc. - Key offerings
  • 11.5 Astellas Pharma Inc.
    • Astellas Pharma Inc. - Overview
    • Astellas Pharma Inc. - Product / Service
    • Astellas Pharma Inc. - Key offerings
  • 11.6 Bristol Myers Squibb Co.
    • Bristol Myers Squibb Co. - Overview
    • Bristol Myers Squibb Co. - Product / Service
    • Bristol Myers Squibb Co. - Key news
    • Bristol Myers Squibb Co. - Key offerings
  • 11.7 Daiichi Sankyo Co. Ltd.
    • Daiichi Sankyo Co. Ltd. - Overview
    • Daiichi Sankyo Co. Ltd. - Product / Service
    • Daiichi Sankyo Co. Ltd. - Key news
    • Daiichi Sankyo Co. Ltd. - Key offerings
  • 11.8 F. Hoffmann La Roche Ltd.
    • F. Hoffmann La Roche Ltd. - Overview
    • F. Hoffmann La Roche Ltd. - Business segments
    • F. Hoffmann La Roche Ltd. - Key news
    • F. Hoffmann La Roche Ltd. - Key offerings
    • F. Hoffmann La Roche Ltd. - Segment focus
  • 11.9 GlaxoSmithKline Plc
    • GlaxoSmithKline Plc - Overview
    • GlaxoSmithKline Plc - Business segments
    • GlaxoSmithKline Plc - Key news
    • GlaxoSmithKline Plc - Key offerings
    • GlaxoSmithKline Plc - Segment focus
  • 11.10 Novartis AG
    • Novartis AG - Overview
    • Novartis AG - Business segments
    • Novartis AG - Key news
    • Novartis AG - Key offerings
    • Novartis AG - Segment focus
  • 11.11 Pfizer Inc.
    • Pfizer Inc. - Overview
    • Pfizer Inc. - Product / Service
    • Pfizer Inc. - Key news
    • Pfizer Inc. - Key offerings
  • 11.12 Teva Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd. - Overview
    • Teva Pharmaceutical Industries Ltd. - Business segments
    • Teva Pharmaceutical Industries Ltd. - Key news
    • Teva Pharmaceutical Industries Ltd. - Key offerings
    • Teva Pharmaceutical Industries Ltd. - Segment focus

12 Appendix

  • 12.1 Scope of the report
  • 12.2 Inclusions and exclusions checklist
    • Inclusions checklist
    • Exclusions checklist
  • 12.3 Currency conversion rates for US$
    • Currency conversion rates for US$
  • 12.4 Research methodology
    • Research methodology
  • 12.5 Data procurement
    • Information sources
  • 12.6 Data validation
    • Data validation
  • 12.7 Validation techniques employed for market sizing
    • Validation techniques employed for market sizing
  • 12.8 Data synthesis
    • Data synthesis
  • 12.9 360 degree market analysis
    • 360 degree market analysis
  • 12.10 List of abbreviations
    • List of abbreviations
Product Code: IRTNTR72532

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Country Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits6: Executive Summary - Chart on Incremental Growth
  • Exhibits7: Executive Summary - Data Table on Incremental Growth
  • Exhibits8: Executive Summary - Chart on Company Market Positioning
  • Exhibits9: Parent Market
  • Exhibits10: Data Table on - Parent Market
  • Exhibits11: Market characteristics analysis
  • Exhibits12: Value Chain Analysis
  • Exhibits13: Offerings of companies included in the market definition
  • Exhibits14: Market segments
  • Exhibits15: Chart on APAC - Market size and forecast 2023-2028 ($ million)
  • Exhibits16: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
  • Exhibits17: Chart on APAC: Year-over-year growth 2023-2028 (%)
  • Exhibits18: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
  • Exhibits19: Historic Market Size - Data Table on Acute Myeloid Leukemia (AML) Treatment Market in APAC 2018 - 2022 ($ million)
  • Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • Exhibits22: Five forces analysis - Comparison between 2023 and 2028
  • Exhibits23: Bargaining power of buyers - Impact of key factors 2023 and 2028
  • Exhibits24: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • Exhibits25: Threat of new entrants - Impact of key factors in 2023 and 2028
  • Exhibits26: Threat of substitutes - Impact of key factors in 2023 and 2028
  • Exhibits27: Threat of rivalry - Impact of key factors in 2023 and 2028
  • Exhibits28: Chart on Market condition - Five forces 2023 and 2028
  • Exhibits29: Chart on Type - Market share 2023-2028 (%)
  • Exhibits30: Data Table on Type - Market share 2023-2028 (%)
  • Exhibits31: Chart on Comparison by Type
  • Exhibits32: Data Table on Comparison by Type
  • Exhibits33: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ million)
  • Exhibits34: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ million)
  • Exhibits35: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
  • Exhibits36: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
  • Exhibits37: Chart on Stem cell transplantation - Market size and forecast 2023-2028 ($ million)
  • Exhibits38: Data Table on Stem cell transplantation - Market size and forecast 2023-2028 ($ million)
  • Exhibits39: Chart on Stem cell transplantation - Year-over-year growth 2023-2028 (%)
  • Exhibits40: Data Table on Stem cell transplantation - Year-over-year growth 2023-2028 (%)
  • Exhibits41: Chart on Others - Market size and forecast 2023-2028 ($ million)
  • Exhibits42: Data Table on Others - Market size and forecast 2023-2028 ($ million)
  • Exhibits43: Chart on Others - Year-over-year growth 2023-2028 (%)
  • Exhibits44: Data Table on Others - Year-over-year growth 2023-2028 (%)
  • Exhibits45: Market opportunity by Type ($ million)
  • Exhibits46: Data Table on Market opportunity by Type ($ million)
  • Exhibits47: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits48: Chart on Market share By Geographical Landscape - 2023-2028 (%)
  • Exhibits49: Data Table on Market share By Geographical Landscape - 2023-2028 (%)
  • Exhibits50: Chart on Geographic comparison
  • Exhibits51: Data Table on Geographic comparison
  • Exhibits52: Chart on China - Market size and forecast 2023-2028 ($ million)
  • Exhibits53: Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Exhibits54: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibits55: Data Table on China - Year-over-year growth 2023-2028 (%)
  • Exhibits56: Chart on Japan - Market size and forecast 2023-2028 ($ million)
  • Exhibits57: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
  • Exhibits58: Chart on Japan - Year-over-year growth 2023-2028 (%)
  • Exhibits59: Data Table on Japan - Year-over-year growth 2023-2028 (%)
  • Exhibits60: Chart on India - Market size and forecast 2023-2028 ($ million)
  • Exhibits61: Data Table on India - Market size and forecast 2023-2028 ($ million)
  • Exhibits62: Chart on India - Year-over-year growth 2023-2028 (%)
  • Exhibits63: Data Table on India - Year-over-year growth 2023-2028 (%)
  • Exhibits64: Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million)
  • Exhibits65: Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million)
  • Exhibits66: Chart on Rest of APAC - Year-over-year growth 2023-2028 (%)
  • Exhibits67: Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%)
  • Exhibits68: Market opportunity By Geographical Landscape ($ million)
  • Exhibits69: Data Table on Market opportunity By Geographical Landscape ($ million)
  • Exhibits70: Impact of drivers and challenges in 2023 and 2028
  • Exhibits71: Overview on criticality of inputs and factors of differentiation
  • Exhibits72: Overview on factors of disruption
  • Exhibits73: Impact of key risks on business
  • Exhibits74: Companies covered
  • Exhibits75: Matrix on companies position and classification
  • Exhibits76: AbbVie Inc. - Overview
  • Exhibits77: AbbVie Inc. - Product / Service
  • Exhibits78: AbbVie Inc. - Key news
  • Exhibits79: AbbVie Inc. - Key offerings
  • Exhibits80: Agios Inc. - Overview
  • Exhibits81: Agios Inc. - Product / Service
  • Exhibits82: Agios Inc. - Key offerings
  • Exhibits83: Astellas Pharma Inc. - Overview
  • Exhibits84: Astellas Pharma Inc. - Product / Service
  • Exhibits85: Astellas Pharma Inc. - Key offerings
  • Exhibits86: Bristol Myers Squibb Co. - Overview
  • Exhibits87: Bristol Myers Squibb Co. - Product / Service
  • Exhibits88: Bristol Myers Squibb Co. - Key news
  • Exhibits89: Bristol Myers Squibb Co. - Key offerings
  • Exhibits90: Daiichi Sankyo Co. Ltd. - Overview
  • Exhibits91: Daiichi Sankyo Co. Ltd. - Product / Service
  • Exhibits92: Daiichi Sankyo Co. Ltd. - Key news
  • Exhibits93: Daiichi Sankyo Co. Ltd. - Key offerings
  • Exhibits94: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits95: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits96: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits97: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits98: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits99: GlaxoSmithKline Plc - Overview
  • Exhibits100: GlaxoSmithKline Plc - Business segments
  • Exhibits101: GlaxoSmithKline Plc - Key news
  • Exhibits102: GlaxoSmithKline Plc - Key offerings
  • Exhibits103: GlaxoSmithKline Plc - Segment focus
  • Exhibits104: Novartis AG - Overview
  • Exhibits105: Novartis AG - Business segments
  • Exhibits106: Novartis AG - Key news
  • Exhibits107: Novartis AG - Key offerings
  • Exhibits108: Novartis AG - Segment focus
  • Exhibits109: Pfizer Inc. - Overview
  • Exhibits110: Pfizer Inc. - Product / Service
  • Exhibits111: Pfizer Inc. - Key news
  • Exhibits112: Pfizer Inc. - Key offerings
  • Exhibits113: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits114: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits115: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits116: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits117: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits118: Inclusions checklist
  • Exhibits119: Exclusions checklist
  • Exhibits120: Currency conversion rates for US$
  • Exhibits121: Research methodology
  • Exhibits122: Information sources
  • Exhibits123: Data validation
  • Exhibits124: Validation techniques employed for market sizing
  • Exhibits125: Data synthesis
  • Exhibits126: 360 degree market analysis
  • Exhibits127: List of abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!